Targets › MAT2A
2 programs from 2 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Jan 2027.
Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The reaction comprises two steps that are both catalyzed by the same enzyme: formation of S-adenosylmethionine (AdoMet) and triphosphate, and subsequent hydrolysis of the triphosphate. (UniProt, P31153)
Open in Phaseline: the race on MAT2A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| IDEAYA Biosciences | IDE397 MAT2A inhibitor | MAT2A | Phase 1 | Solid Tumor; NSCLC Adenocarcinoma | Jan 2027 |
| Servier Bio-Innovation | S095035 MAT2A inhibitor | MAT2A | Phase 1 | MTAP-deleted Solid Tumors | May 2027 |
Solid Tumor (1) NSCLC Adenocarcinoma (1) MTAP-deleted Solid Tumors (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.